Jazz Pharmaceuticals (JAZZ) reported $4.3B in revenue for fiscal 2025, +4.9% year on year. That ranks #894 by revenue among 2853 SEC filers and #78 in Healthcare. It posted a net loss of −$356M for the same year. Revenue has grown 21.7% a year on average since 2011 ($272M then). The fiscal 2025 balance sheet shows $11.7B in total assets, $1.4B in cash and $4.3B in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $4.3B | +4.9% | FY20252025-12-31 |
| Gross profit | Not reported | — | |
| Operating incomeOperatingIncomeLoss | −$430M | −$1.1B | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$356M | −$916M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.4B | −2.9% | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $58.8M | +54.3% | FY20252025-12-31 |
| Total assetsAssets | $11.7B | −2.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $4.3B | +5.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $1.4B | −42.3% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $4.3B | −28.8% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $1.1B | $293M | Open → |
| Q2 20262026-06-30 | $1.2B | $193M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Where this sits in its sector
Each bar is the spread of the whole sector: the box covers the middle half of companies, the line inside it the median, and the triangle this company. The axis is clipped at the 5th and 95th percentile so a single outlier does not flatten it.
| Where this sits in its sector | FY2025 | Position in sector |
|---|---|---|
| Net marginRank 139 of 161 companies compared | −8.3% | |
| Operating marginRank 143 of 160 companies compared | −10.1% | |
| R&D as share of revenueRank 29 of 102 companies compared | 18.3% | |
| Cash as share of revenueRank 21 of 160 companies compared | 32.6% |
All four are ratios derived from two reported lines, not single filing items. Peer group: companies in the same sector with revenue of $1bn or more; loss-making companies are included.
Profile
- Legal name
- Jazz Pharmaceuticals Plc
- Ticker
- JAZZ
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001232524
Filings
- 10-QAug 3, 2026Open filing →
- 10-QMay 5, 2026Open filing →
- 10-KFeb 24, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| DexcomDXCM | $4.7B | $836M |
| Cno FinancialCNO | $4.5B | $229M |
| Idexx LaboratoriesIDXX | $4.3B | $1.1B |
| Jazz PharmaceuticalsJAZZ | $4.3B | −$356M |
| PerrigoPRGO | $4.3B | −$1.4B |
| Cooper CompaniesCOO | $4.1B | $375M |
| Align TechnologyALGN | $4.0B | $410M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Jazz Pharmaceuticals — Key figures |url=https://companiesranked.com/en/company/jazz-pharmaceuticals |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Jazz Pharmaceuticals — Key figures. CompaniesRanked. https://companiesranked.com/en/company/jazz-pharmaceuticalsBibTeX
@misc{companiesranked-en-company-jazz-pharmaceuticals-2026,
author = {{CompaniesRanked}},
title = {{Jazz Pharmaceuticals — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/jazz-pharmaceuticals}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001232524-26-000013 · February 24, 2026
{{cite web |title=Jazz Pharmaceuticals — Key figures — 10-K (0001232524-26-000013) |url=https://www.sec.gov/Archives/edgar/data/1232524/000123252426000013/jazz-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.